Companies › Forte Biosciences
1 active drug program in 4 registered trials: 3 Phase 1, 1 Phase 2; Gastroenterology, Immunology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FB102 JAK inhibitor | – | Phase 2 | Celiac Disease; Vitiligo; Healthy Volunteer; Alopecia Areata | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06905873 | FB102 | Phase 1 | Vitiligo | Immunology | Dec 2026 |
| NCT07623057 | FB102 | Phase 1 | Healthy Volunteer | Other | Feb 2027 |
| NCT06982963 | FB102 | Phase 2 | Celiac Disease | Gastroenterology | Feb 2027 |
| NCT07205159 | FB102 | Phase 1 | Alopecia Areata | Immunology | Mar 2027 |
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Zealand Pharma LyGenesis Mikrobiomik Healthcare Company Bluefin Biomedicine Tego Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.